Literature DB >> 25727384

Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.

David M Charytan1, Steven Fishbane2, Jolanta Malyszko3, Peter A McCullough4, David Goldsmith5.   

Abstract

The association between chronic kidney disease (CKD) and cardiovascular disease (CVD) is well established, and there is mounting evidence of interorgan cross talk that may accelerate pathologic processes and the progression of organ dysfunction in both systems. This process, termed cardiorenal syndrome (CRS) by the Acute Dialysis Quality Initiative, is considered a major health problem: patients with CKD and CVD are at much higher risk of mortality than patients with either condition alone. To date, the majority of CRS research has focused on neurohormonal mechanisms and hemodynamic alterations. However, mounting evidence suggests that abnormalities in the normal pathophysiology of the bone-mineral axis, iron, and erythropoietin play a role in accelerating CKD and CVD. The goal of this article is to review the role and interrelated effects of the bone-mineral axis and anemia in the pathogenesis of chronic CRS.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiorenal syndrome (CRS); anemia; bone-mineral axis; cardiovascular disease (CVD); chronic kidney disease (CKD); end-stage renal disease (ESRD); erythropoietin (EPO); fibroblast growth factor 23 (FGF-23); heart failure (HF); iron; phosphate; renal dysfunction; review; vitamin D

Mesh:

Substances:

Year:  2015        PMID: 25727384      PMCID: PMC4516683          DOI: 10.1053/j.ajkd.2014.12.016

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  100 in total

1.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

Authors:  A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

2.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.

Authors:  Tamara B Horwich; Gregg C Fonarow; Michele A Hamilton; W Robb MacLellan; Jeff Borenstein
Journal:  J Am Coll Cardiol       Date:  2002-06-05       Impact factor: 24.094

Review 3.  Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD.

Authors:  Jodie L Babitt; Herbert Y Lin
Journal:  Am J Kidney Dis       Date:  2010-02-26       Impact factor: 8.860

4.  Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors.

Authors:  Hiroaki Ogata; Eberhard Ritz; Giulio Odoni; Kerstin Amann; Stephan R Orth
Journal:  J Am Soc Nephrol       Date:  2003-04       Impact factor: 10.121

Review 5.  Hemochromatosis: genetics and pathophysiology.

Authors:  Ernest Beutler
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

6.  High phosphate directly affects endothelial function by downregulating annexin II.

Authors:  Giovana Seno Di Marco; Maximilian König; Christian Stock; Anne Wiesinger; Uta Hillebrand; Stefanie Reiermann; Stefan Reuter; Susanne Amler; Gabriele Köhler; Friedrich Buck; Manfred Fobker; Philipp Kümpers; Hans Oberleithner; Martin Hausberg; Detlef Lang; Hermann Pavenstädt; Marcus Brand
Journal:  Kidney Int       Date:  2012-08-22       Impact factor: 10.612

Review 7.  Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.

Authors:  Karien van der Putten; Branko Braam; Kim E Jie; Carlo A J M Gaillard
Journal:  Nat Clin Pract Nephrol       Date:  2008-01

8.  Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.

Authors:  James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

9.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

10.  Correction of iron deficiency in the cardiorenal syndrome.

Authors:  Donald S Silverberg; Dov Wexler; Adrian Iaina; Doron Schwartz
Journal:  Int J Nephrol       Date:  2011-04-19
View more
  16 in total

1.  A new in vitro model to delay high phosphate-induced vascular calcification progression.

Authors:  Paola Ciceri; Francesca Elli; Laura Cappelletti; Delfina Tosi; Paola Braidotti; Gaetano Bulfamante; Mario Cozzolino
Journal:  Mol Cell Biochem       Date:  2015-09-07       Impact factor: 3.396

2.  Characterization of an Animal Model to Study Risk Factors and New Therapies for the Cardiorenal Syndrome, a Major Health Issue in Our Aging Population.

Authors:  Anja Verhulst; Ellen Neven; Patrick C D'Haese
Journal:  Cardiorenal Med       Date:  2017-05-24       Impact factor: 2.041

3.  Possible therapeutic impact of the iron chelation on renal fibrosis.

Authors:  Kouichi Tamura; Kazushi Uneda; Kengo Azushima; Hiromichi Wakui; Kotaro Haruhara
Journal:  Hypertens Res       Date:  2015-04-16       Impact factor: 3.872

Review 4.  Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature.

Authors:  Feby Savira; Ruth Magaye; Danny Liew; Christopher Reid; Darren J Kelly; Andrew R Kompa; S Jeson Sangaralingham; John C Burnett; David Kaye; Bing H Wang
Journal:  Br J Pharmacol       Date:  2020-05-13       Impact factor: 8.739

Review 5.  Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Authors:  Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling
Journal:  Nat Rev Nephrol       Date:  2016-08-30       Impact factor: 28.314

Review 6.  Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?

Authors:  Ruth F Dubin; Sanjiv J Shah
Journal:  Curr Heart Fail Rep       Date:  2016-06

7.  Iron metabolism in hemodialyzed patients - a story half told?

Authors:  Jolanta Malyszko; Ewa Koc-Zorawska; Nomy Levin-Iaina; Itzchak Slotki; Joanna Matuszkiewicz-Rowinska; Irena Glowinska; Jacek S Malyszko
Journal:  Arch Med Sci       Date:  2014-12-22       Impact factor: 3.318

8.  Renalase attenuates hypertension, renal injury and cardiac remodelling in rats with subtotal nephrectomy.

Authors:  Jianyong Yin; Zeyuan Lu; Feng Wang; Zhenzhen Jiang; Limin Lu; Naijun Miao; Niansong Wang
Journal:  J Cell Mol Med       Date:  2016-02-29       Impact factor: 5.310

9.  An Isoform of Nedd4-2 Plays a Pivotal Role in Electrophysiological Cardiac Abnormalities.

Authors:  Shintaro Minegishi; Tomoaki Ishigami; Hisho Kawamura; Tabito Kino; Lin Chen; Rie Nakashima-Sasaki; Hiroshi Doi; Kengo Azushima; Hiromichi Wakui; Yumi Chiba; Kouichi Tamura
Journal:  Int J Mol Sci       Date:  2017-06-14       Impact factor: 5.923

10.  Fibroblast growth factor 23, iron and inflammation - are they related in early stages of chronic kidney disease?

Authors:  Ewelina Lukaszyk; Mateusz Lukaszyk; Ewa Koc-Zorawska; Anna Bodzenta-Lukaszyk; Jolanta Malyszko
Journal:  Arch Med Sci       Date:  2016-03-17       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.